The estimated Net Worth of Marc Grasso is at least 5.07 百万$ dollars as of 3 September 2024. Marc Grasso owns over 7,297 units of Kura Oncology Inc stock worth over 2,599,111$ and over the last 5 years he sold KURA stock worth over 357,579$. In addition, he makes 2,112,280$ as Chief Financial Officer and Chief Business Officer at Kura Oncology Inc.
Sign up
Marc Grasso KURA stock SEC Form 4 insiders trading
Marc has made over 11 trades of the Kura Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,297 units of KURA stock worth 35,609$ on 3 September 2024.
The largest trade he's ever made was exercising 10,000 units of Kura Oncology Inc stock on 14 September 2020 worth over 290,000$. On average, Marc trades about 3,998 units every 88 days since 2020. As of 3 September 2024 he still owns at least 130,740 units of Kura Oncology Inc stock.
You can see the complete history of Marc Grasso stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marc Grasso biography
Dr. Marc Grasso M.D. serves as Chief Financial Officer and Chief Business Officer of the Company. He has served as our Chief Financial Officer and Chief Business Officer since August 2018. Prior to joining us, he served as Managing Director at Stifel Financial Corp., an investment bank and financial services company, from March 2013 to July 2018, where he was responsible for building and managing Stifel’s west coast life sciences and biotechnology investment banking business. From June 2010 to February 2013, Dr. Grasso was Managing Director of Investment Banking in the Global Healthcare Group at UBS Group AG, focused on the biotechnology sector, and from May 2008 to June 2010 he was Managing Director of Investment Banking at Leerink Swann LLC (“Leerink”), a specialist investment bank focused on the healthcare sector, where he was instrumental in the west coast expansion of their franchise. Dr. Grasso joined Leerink from Morgan Stanley, where he served as an Executive Director of Investment Banking in the Global Healthcare Group. Prior to joining Morgan Stanley, he was Vice President of Investment Banking in the Global Healthcare Group of Credit Suisse First Boston. He began his career in investment banking at Deutsche Banc Alex. Brown Inc. Dr. Grasso received his M.D. from The Johns Hopkins University School of Medicine, where he also performed research in molecular oncology. He obtained an A.B. in molecular biology with honors from Princeton University.
What is the salary of Marc Grasso?
As the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc, the total compensation of Marc Grasso at Kura Oncology Inc is 2,112,280$. There are 2 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of 3,485,030$.
How old is Marc Grasso?
Marc Grasso is 47, he's been the Chief Financial Officer and Chief Business Officer of Kura Oncology Inc since 2019. There are 18 older and 2 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
What's Marc Grasso's mailing address?
Marc's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Kura Oncology Inc
Over the last 6 years, insiders at Kura Oncology Inc have traded over 16,903,587$ worth of Kura Oncology Inc stock and bought 50,000 units worth 575,000$ . The most active insiders traders include Faheem Hasnain、Troy Edward Wilson、Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of 626,260$. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth 57,922$.
What does Kura Oncology Inc do?
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
What does Kura Oncology Inc's logo look like?
Complete history of Marc Grasso stock trades at Kura Oncology Inc、Alector
Kura Oncology Inc executives and stock owners
Kura Oncology Inc executives and other stock owners filed with the SEC include:
-
Kathleen Ford,
Chief Operating Officer -
Troy Wilson,
Chairman of the Board, President, Chief Executive Officer -
Marc Grasso,
Chief Financial Officer and Chief Business Officer -
James Basta,
Chief Legal Officer and Secretary -
Dr. Troy Edward Wilson,
Chairman, CEO & Pres -
Dr. Troy Edward Wilson J.D., Ph.D.,
Chairman, CEO, Pres & Principal Financial Officer -
Dr. Marc Grasso,
CFO & Chief Bus. Officer -
Kathleen Ford,
Chief Operating Officer -
Kirsten Flowers,
Chief Commercial Officer -
Dr. Marc Grasso M.D.,
Advisor -
Dr. Stephen Dale M.D.,
Chief Medical Officer -
Diane Parks,
Independent Director -
Robert Hoffman,
Independent Director -
Faheem Hasnain,
Lead Independent Director -
Thomas Malley,
Independent Director -
Steven Stein,
Independent Director -
Mary Szela,
Independent Director -
Bridget Martell,
Acting Chief Medical Officer -
Kirsten Flowers,
Chief Commercial Officer -
Stephen Dale,
Chief Medical Officer -
Thomas Doyle,
Principal Accounting Officer & Sr. VP of Fin. and Accounting -
Dr. Nic G. Scalfarotto,
Sr. VP of Regulatory Affairs -
Dr. Roger Bakale Ph.D.,
VP and Head of CMC, Clinical & Commercial Manufacturing -
Teresa Brophy Bair Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
James E. Basta J.D., Esq.,
Chief Compliance Officer & Corp. Sec. -
Pete De Spain,
VP of Investor Relations & Corp. Communications -
Teresa Brophy Bair,
Chief Legal Officer -
Antonio Gualberto,
Head of Development & CMO -
Pingda Ren,
SVP Chemistry&Pharma Sciences -
Annette North,
SVP, General Counsel -
Carol Schafer,
-
Helen Louise Collins,
-
Brian T. Powl,
Chief Commercial Officer -
Thomas James Doyle,
SVP, Finance & Accounting